导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.79% | 57/147 |
| 近一周 | -2.54% | 27/153 |
| 近一月 | -1.70% | 52/153 |
| 近一季 | -0.92% | 40/153 |
| 近半年 | -3.98% | 54/149 |
| 近一年 | -10.44% | 31/144 |
| 近两年 | 35.80% | 51/119 |
| 近三年 | 31.98% | 25/89 |
| 成立以来 | 0.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.28% 136/360 |
-8.15% 252/366 |
- - |
- - |
| 2025 | 25.29% 70/358 |
14.44% 104/340 |
3.70% 201/348 |
11.39% 133/354 |
-5.22% 215/358 |
| 2024 | 21.62% 92/329 |
-2.80% 197/280 |
8.55% 40/310 |
18.33% 95/318 |
-2.59% 186/329 |
| 2023 | -11.35% 171/275 |
0.67% 148/205 |
-2.02% 135/230 |
-7.36% 201/262 |
-2.98% 210/276 |
| 2022 | -8.03% 33/201 |
-7.06% 49/153 |
4.85% 59/164 |
-15.82% 102/189 |
12.11% 83/202 |
| 2021 | -15.01% 78/150 |
4.16% 86/312 |
0.66% 215/328 |
-13.52% 252/358 |
-6.27% 85/151 |
| 2020 | -7.32% 64/103 |
-13.65% 175/280 |
3.79% 244/295 |
-6.47% 275/299 |
10.56% 113/305 |
| 2019 | 11.87% 63/88 |
9.35% 137/258 |
1.75% 121/267 |
-5.82% 232/253 |
6.75% 124/266 |
| 2018 | - - |
- - |
- - |
- - |
-7.22% 86/241 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 南方恒生生物科技ETF(QDII) | 1.1206 | 25.14% |
| 华宝标普油气上游股票美元A | 0.1538 | 24.94% |
| 广发中证香港创新药ETF发起式联接(QDII)A | 1.3401 | 24.24% |
| 华夏恒生ETF联接C VS. 建信富时100指数(QDII)人民币A(539003) |